Clinical Trial Update: Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating antigen-specific engineered immune effectors for ovarian cancer is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Antigen-specific Engineered Immune Effectors

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION